Can I get Arthrosamid on the NHS

No — at present, Arthrosamid does not appear to be a routinely available NHS injection for knee osteoarthritis in the UK. The clearest public signals point the other way: the Health Research Authority summary for an NHS study says that, for knee OA, "currently only steroid injections are available as part of NHS treatment", and NICE's prioritisation page for Arthrosamid says the technology was "not selected" for Health Technology Evaluation because there is "insufficient evidence".

There has still been NHS involvement, but mainly through research rather than standard commissioning. A study linked to The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust was launched to check clinical effectiveness in a UK NHS setting and to clarify which patients are most likely to benefit. That is an important distinction in 2024-2025: a treatment being studied in the NHS is not the same as it being routinely funded by the NHS.

The practical expectation for most patients, then, is private access unless a specific local research pathway exists. Retrieved UK provider prices for one knee sit broadly around £2,900 to £3,200, but that is not a national tariff and the package can differ by clinic — for example, whether consultation, ultrasound guidance, antibiotics and follow-up are included.

Why NHS access is still limited

The bottleneck is the type of proof still missing. On NICE’s GID-MT606 page, Arthrosamid was not taken forward for Health Technology Evaluation because there was “insufficient evidence”. That is different from saying the injection cannot help; it means the published case has not yet reached the level usually needed for routine NHS adoption.

The gap shows up in the studies most often cited. One 12-month paper followed 49 patients in an open-label design, and a later 5-year extension enrolled 35 of them, with 27 completing follow-up. Those results are encouraging, with sustained symptom improvement reported over time and no serious adverse events attributed to the device, but they are still mainly single-arm data rather than stronger head-to-head evidence against existing care pathways.

For NHS commissioning in England in 2024-2025, that matters. Decision-makers often need clearer comparative evidence, better definition of which patients benefit most, and a more robust case for broad funding than early before-and-after studies can provide. That is why patient interest and promising long-term symptom data may coexist with limited routine NHS access for some time.

What the private cost usually covers

A similar-looking quote is not always a like-for-like quote. Even when providers sit in a broadly similar band for one knee, the package can be different. For example, London Cartilage Clinic publishes a package that includes the consultation, ultrasound, the product, the injection protocol and a six-week follow-up; the Horder Centre listing is presented more simply as a “single knee injection”; and medneo describes Arthrosamid as a self-pay treatment at its London centre.

When comparing clinics, the moving parts usually include:

• whether an initial consultation is included or billed separately
• whether any imaging review is part of the decision-making
• whether ultrasound guidance is included on the day
• whether medicines or aftercare items are bundled
• whether follow-up is included, such as a six-week review
• whether the figure is for the injection alone or a fuller package

Another common source of confusion is that quotes are often framed per knee. A published single-knee price does not translate neatly to treatment on both sides, and providers that show stepped pricing for more than one box or injection make clear how quickly the total can change. A written itemised breakdown is usually the safest way to compare the real out-of-pocket cost.

When paying privately may be reasonable

Private Arthrosamid sits in a fairly narrow part of the pathway. At Parkside Hospital, Nuffield Health describes it for mild-to-moderate knee osteoarthritis when physiotherapy, lifestyle changes or other injections have not given enough relief, and not for inflammatory arthritis or severe “bone-on-bone” disease. In other words, the more plausible self-funding case is someone whose knee is still a preservation problem rather than a replacement problem.

What can make the spend feel reasonable for some people is the combination of one injection and the possibility of longer symptom control. The published studies are not the strongest kind of comparative evidence, but they do report improvement at 52 weeks and sustained benefit in a 5-year extension after a single treatment. That may appeal to patients who want to stay non-surgical for the time being and are weighing the cost against the chance of fewer treatment decisions over the next several years.

The key issue is expectation-setting. Arthrosamid is being considered here as a symptom-management option, not as a way to reverse advanced joint damage, and the available studies are still mainly “open-label” rather than head-to-head NHS-style commissioning evidence. A reasonable private candidate is therefore usually someone with persistent day-to-day pain, the right stage of osteoarthritis, and a clear understanding before treatment that benefit is possible but not guaranteed.

When it is the wrong fit

Severe “bone-on-bone” knee osteoarthritis is usually where the fit starts to fall away. At Parkside Hospital, Nuffield Health describes Arthrosamid for mild-to-moderate disease and says severe bone-on-bone arthritis is a setting where knee replacement is often more effective. Once the knee has moved from symptom control towards end-stage mechanical wear, a single injection is less likely to match the problem being treated.

A second boundary is the material itself. Arthrosamid is presented as a long-lasting, “non-biodegradable” hydrogel, and the HRA summary describes it as 97.5% water with 2.5% cross-linked polyacrylamide. That means the trade-off is not only the appeal of one injection: it is also permanence. The practical point is therefore not to chase an exact event rate, but to recognise what it means to choose a material designed to remain in the joint.

That permanence is one reason the decision needs careful discussion with a knee specialist. The useful takeaway is about fit rather than fear: a treatment may be reasonable in a selected knee and still be the wrong choice for someone whose arthritis already looks closer to replacement than preservation.

Questions to ask before you self-fund

Before any self-pay decision, it helps to turn the discussion into a short checklist rather than rely on a single provider page or quote. With NICE saying the evidence for Arthrosamid was “insufficient” for guidance development, the key issue is not just availability but why it is being suggested for this particular knee.

• How advanced is the arthritis on a recent X-ray or MRI, and does that stage still fit an injection-led plan?
• What has already been tried properly — for example physiotherapy, activity change, weight management or earlier injections — and what was the result?
• What is the realistic goal in day-to-day terms: less pain on stairs, longer walking distance, better sleep, or simply a delay before surgery is reconsidered?
• What evidence supports Arthrosamid against other symptom-control or joint-preservation options in this case?
• What exactly is included in the one-knee fee: the first consultation, ultrasound guidance, and follow-up, or are some of those extra?

The sensible next step is a specialist knee review in an appropriate clinical setting, so Arthrosamid is weighed as one comparison option rather than the decision being driven by a quote alone.